These effects are often temporary
Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. Semaglutide and Its Impact on Weight Loss Several studies have been published looking at the effects of Semaglutide injections on weight loss: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity This study which was published in 2022 looked at the effects of Semaglutide weekly 1.7-mg or 2.4-mg subcutaneous injections for 3 to 6 months
Tirzepatide is Mounjaro at various doses
We see this all the time in our patient population
From day one, the staff was incredibly supportive, knowledgeable, and genuinely invested in helping me reach my goals
We would also like to thank the dedicated employees of the microbiology laboratories at the Clifton, NJ, Marlborough, MA, Atlanta, GA, West Hills, CA, Wood Dale, IL, Miami, FL, Tampa, FL, Chantilly, VA, Dallas, TX, and Lenexa, KS, who diligently and enthusiastically identified and shipped the specimens to be included in the study